Given its modern-day ubiquity, it's easy to forget that pharma DTC didn't exist until the 1980s rolled around.
Sharecare acquires virtual-reality developer; Novo Nordisk to cut 1,000 jobs; the FDA approves Medtronic's automated insulin pump
Really? Is this the new healthcare math — the fewer the insurance companies, the greater the competition and the lower the premiums?
Discovering Meaningful Insights in Patient Journeys: Identifying Hidden Patterns Using Advanced AnalyticsSeptember 21, 2016
During this seminar, attendees will learn how advanced data analytics can be applied to gain a measurable competitive advantage.
In this webcast, TrialCard VP of analytic services Paul LeVine and senior analytic consultant Robert Leedom underscore how affordability programs provide the ideal venue for focusing on adherence issues.
In this sponsored podcast, MM&M's Larry Dobrow speaks with Robert Leedom, senior analytics consultant at TrialCard, and Paul LeVine, VP of analytic services for TrialCard, about how to reach patients by leveraging brand data.
The latest TV campaign from Mars features a woman with cerebral palsy joking about her love life.
The availability of online medical information is changing the way doctors share and receive information — both among themselves and with their patients.
Will this payer pressure pose an existential threat to co-pay cards even though patients love them?
Many patients find it difficult to ask questions of their physician.
It's unlikely that pharma will ever achieve the degree of consumer love directed at Amazon and Apple but the shift taking place will open up doors for pharma organizations.
The power of hackathons is now magnified because of the power of the internet and social media, giving both patients and healthcare professionals a global platform for their voices.
Imagine if the agencies pitching us mocha lattes faced these consumer beliefs: The latte will hurt when I drink it. The latte might leave me with a rash or cause me to vomit.
In the webinar, 5 Keys to Success in the New Patient Economy, you'll learn tips and strategies for transforming your patient engagement model.
Drugmakers test out virtual reality, partner with companies like Spotify, and go for the cinematic at Cannes Lions.
Despite the increasing importance of the CIO post, top technology professionals still find it hard to break into the uppermost ranks at life-sciences companies.
In partnership with inVentiv Health, MM&M found a millennial doctor to ask about her frustrations with the existing pharma marketing model to her willingness to text patients.
The truth is, biopharma marketing and behavioral psychology have a lot in common. Ultimately, both aim to nudge people to make a medical or lifestyle change that could positively impact their health.
Where are the discussions about applying proven behavior change models or the principles of adult learning and health literacy?
It's a common refrain in healthcare and among patients, providers, and payers: Despite massive investment, no one has figured out how to change human behavior.
Maybe we have just forgotten the true reason why marketing exists in organizations.
At the MM&M Transforming Healthcare conference, Iyengar told attendees how to take into account a consumer's behavior and emotion when marketing medical products.
Wieden+Kennedy Portland's VR work for the National Multiple Sclerosis Society lets wheelchair-bound patients experience their favorite activities again, like dancing or surfing.
Companies spend $2 billion per year recruiting patients for clinical trials. A survey of 702 adults, conducted from December 2015 to January 2016, points to a need for more awareness.
Monique Levy, who's spent more than a decade helping drugmakers understand technology shifts, has joined PatientsLikeMe, the online discussion platform for people with chronic illness.
If you truly understand who your high writers and compliant patients are, you'll understand when and how to communicate with prospects that look and act like them.
Maybe it's time for pharma and healthcare marketers to put all the "patient-centric" talk on the shelf — not the actual paying-attention-to-patients part of it, but the trumpeting of it as the most noble of life-science virtues.
The motivating force behind My GI Health met initial resistance. After all, it came from a company executive who professed that his goal was to benefit all companies within that therapeutic area.
Tom McCourt says he's "a marketing guy who hopefully understands a little about drug development" even as he guided drugs like Prilosec to market.
There are big changes underway in the doctor-patient relationship, a study suggests, and it's a new reality to which biopharma must adjust.
- Sunovion hires former BI exec as VP of marketing
- Five things for pharma marketers to know: Tuesday, October 25, 2016
- Five things for pharma marketers to know: Monday, October 24, 2016
- Five things for pharma marketers to know: Wednesday, October 26, 2016
- If Roche's Ocrevus is approved, the already competitive MS market will gain another player
- Merck educates doctors about biosimilars, long before it will sell one in the U.S.
- 4 trends with the potential to change behavior in the patient journey
- 2016 Pharma Report: All the data in one place
- What do physicians think about biosimilars?
- Novartis considers new sales model for experimental cancer therapy